# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Goldman Sachs analyst David Roman initiates coverage on Boston Scientific (NYSE:BSX) with a Buy rating and announces Price T...
Argus Research analyst John Eade maintains Boston Scientific (NYSE:BSX) with a Buy and raises the price target from $80 to $95.
Citigroup analyst Joanne Wuensch maintains Boston Scientific (NYSE:BSX) with a Buy and raises the price target from $85 to $87.
In addition to evaluating the safety and performance of the EMPOWER LP as a standalone pacemaker, the trial evaluated the abili...